by Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, Dillon J-A, Kularatne R, Heim J, Hooft van Huijsduijnen R, Hook EW, Lahra M, Lewis DA, Ndowa F, Shafer WM, Tayler L, Workowski K, Unemo M, Balasegaram M. PLOS Medicine, July 2017, doi.org/10.1371/journal.pmed.1002366.
Summary: The choice of antimicrobials to treat a rising number of gonorrhea cases is very limited. Resistance has been reported to extended-spectrum cephalosporins, the mainstay of currently recommended treatment, and there are only 3 new chemical entities in the pipeline. GARDP has worked with experts from different regions to draft “ideal” and “acceptable” Target Product Profiles for the treatment of gonorrhea. GARDP has developed a 7-year plan to meet the urgent need for new drugs to treat gonorrhea, which includes exploring the introduction of a new clinical entity; the identification of existing, suitable partner drugs; the recovery of previously abandoned, out-of-favor, and withdrawn antibiotics; and the development of simplified treatment guidelines for the empiric management of sexually transmitted infections.